SPASMOLYTICALLY ACTIVE (+)S-ENANTIOMER OF SECOVERINE

Abstract: The invention concerns spasmolytically active phar­ maceutical compositions, and the preparation thereof, con­ taining (+) S-1-cyclohexyl-4-[ethyl-(p-methoxy-α-methyl­ phenethyl)amino]-1-butanone or a salt thereof as the active component. It has been found that this (+) S-enantiomer is about twice as active as the racemate (which is known as secover­ ine). This better activity is not related with a proportional increase of undesired side-effects.

Description: Spasmolytically active (+) S enantiomer of secoverine. The invention relates to a method of preparing pharmaceutical compositions which comprise a spasmolytically active compound of formula 1 of the formula sheet, or a salt thereof, as an active substance, and to the compositions thus obtained. The invention furthermore relates to a method of preparing the (+) - enantiomer of 1-cyclohexyl-4- Cethyl- -(p-methoxy-aC-methyIphenethyl)ami03-I-butanone (which racemate is known as secoverinD or a salt thereof, to the (+) -enantiomer thus to be obtained and the salts thereof, and to a method of controlling spasms by means of the said compound or a salt thereof. It is known from Netherlands Patent Application 7404733 that a group of compounds of which secoverine forms part has a specific, spasmolytic activity on the smooth musculature of the tractus gastrointestinalis, the tractus urogenitalis and the bronchial system. It has now been found that the anticholinergic spasmolytic activity in peripheral organs of the (+)-enantiomer of secoverine is approximately twice as strong as that of the racemate. Although it is known of some anticholinergics having an optically active carbon atom in the molecule, that the enantiomers have a different activity, this was not known of secoverine. It is surprising that the found difference in activity in peripheral organs between the (+)- and (-)-enantiomers of secoverine is so large: the (+)-enantiomer of secoverine is approximately 100 times as active as the (-)enantiomer. It has furthermore been found that, in contrast with what might be expected on the basis of the 100 times larger activity of the (+)-enantiomer of secoverine with respect to the (-)-enantiomer, there is no or substantially no difference between the two enantiomers as regards the noradrenaline (NA)-re-uptake-inhibiting and NA-potentiating properties. As regards the less desirable local anaesthetic properties, the (-)-enantiomer is clarly more active in view of the (+)-enantiomer. The advantages of the twice as strong peripheral activity and the approximately equal to smaller undesired side effects of the (+)-enantiomer of secoverine in comparison with the racemate are: 1) only half the dose is necessary to obtain the same thera peutic effect; 2) that as a result of this the non-desired side effects are halved at least. In a few tests suitable for this purpose, the spasmolytic activity of the (+)-enantiomer of secoverine was compared both in vitro and in vivo with that of the racemate and/or the (-)-enantiomer. a) Peripheral spasmolytic activity in vitro These tests were carried out according to the normal 4 -point analysis in which the terminal guinea pig ileum was used as isolated organ and carbachol was used as a cholinergic spasmogen. The required organs were isolated from killed guinea pigs and the contents and adherent tissues were carefully removed from suitable pieces. The said organs were then suspended in a bath containing 50 ml of Tyrode solution through which oxygen was led. The spasmogenically active substance (carbachol) was added to the bath iriter- mittciitly and, after a constant response to the spasmogen had been obtained, the spasmolytic activity of the sub stances to be tested was measured by adding them to the bath 30 seconds prior to the spasmogen. The relative activity of the (+)-enantiomer of secoverine as compared with the racemate was calculated from a series of 4-point assays: the (+)-enantiomer of secoverine was 1.86 times as active as the racemate. Similar results were obtained by using rat jeju num as an organ and using furtrethonium as a spasmogeni cally active substance: the (+)-enantiomer of secoverine now was 2.10 times as active as the racemate. b) Affinity to the muscarine receptor According to the method of J.M. van Rossum, Arch. Int. Pharmacodyn., 143 (1963) 299 cumulative dose-response curves were determined. For this purpose, rat jejunum was used as an organ and furtrethonium was used as a spasmogenically active substance. Affinity constants were expressed as pA2-values. Both enantiomers of secoverine and the racemate gave a good shift to the right of the dose response curves of furtrethonium without the maximum of the curves being changed: EMI3.1 <tb> <SEP> compound <SEP> pA2 <tb> (+)-enantiomer <SEP> of <SEP> 8.10 <tb> <SEP> secoverine <tb> <SEP> racemate <SEP> 7.90 <tb> (-)-enantiomer <SEP> of <SEP> 5.88 <tb> <SEP> secoverine <tb> It may be concluded from these results that the (+)-enantiomer of secoverine has a more than 100 times larger activity than the (-)-enantiomer. c) Anticholinergic activity in vivo These tests were carried out according to the method by J.M.A. Zwagemakers, Arzneimittelforschung, 30 (II), (1980), 1517-1526 in which carbachol was used as a spasmogenical ly active substance. After a constant response to the spasmogen had been obtained, the compound to be tested was administered intravenously (i.v.) to guinea pigs 3 minutes prior to the next quantity of spasmogenically active sub stance. The activity of the compounds was determined for 52 minutes. Contractions obtained after preceding admini stration of the substance to be tested were expressed as percentages of the average of two control values and were plotted graphically. The average percentage of inhibition during the period of 52 minutes was calculated from the area under the curve, and the maximum inhibition and the duration of the spasmolytic activity were estimated by means of the time-contraction curve. The spasmolytic acti vity is considered to be terminated when two successive contractions show less than 20% inhibition. The following results were obtained: EMI4.1 <tb> compound <SEP> Average <SEP> % <SEP> of <SEP> Average <SEP> % <SEP> of <SEP> Duration <SEP> of <tb> <SEP> total <SEP> inhibition <SEP> max. <SEP> inhibition <SEP> act. <SEP> in <SEP> min. <tb> (+)-enantiomer <tb> of <SEP> secoverine <SEP> 51 <SEP> 69 <SEP> > 52 <tb> 0.05 <SEP> mg/kg/i.v. <tb> (+)-enantiomer <tb> of <SEP> secoverine <SEP> 88 <SEP> 93 <SEP> )52 <tb> 0.10 <SEP> mg/kg/i.v. <tb> Racemate <SEP> 0.10 <SEP> 55 <SEP> 69 <SEP> > 52 <tb> mg/kg/i.v. <SEP> <tb> It appears from the results that the (+)-enantiomer of secoverine is about twice as active as the racemate. d) Potentiation of the activity of noradrenaline on the vas deferens of the rat in vitro The test used is a modification of the method as described by Ursillo and Jacobsen, J. Pharmacol. Ex. Ther. 148, (1965), 247. A significant noradrenaline potentiation was found both of the racemate and of the (+)- and (-)-enan tiomer. The smallest dose which gave a potentiating effect was 1 x 10 7M, and the potentiating activity was maximum in a quantity of 5 x 10 7M. Higher dosages caused a non -specific decrease of the maximum of the noradrenaline curve. In addition to a significant shift to the left, the noradrenaline curves obtained under the influence of seco verine or one of the enantiomers, showed a rather strong increase of the maximum contraction. For quantifying the effect at the 50% point of the contraction curve (maximum of the control noradrena line curve = 100%), the shift of the curve obtained with the compound to be tested (expressed as DR) was measured. The pP2-values were calculated in the same manner as the pA2-values mentioned sub b), according to the equation PP2 = -log EsecoverinC + log (DR-7). Hence the pP2-value is the negative logarithm of the molar concentration which gives a shift to the left of a factor 2. EMI5.1 <tb> <SEP> compound <SEP> pP2-value <tb> <SEP> racemate <SEP> 6.51 <tb> (+)-enantiomer <SEP> of <SEP> <SEP> 6.58 <SEP> <tb> <SEP> secoverine <tb> (-)-enantiomer <SEP> of <SEP> 6.77 <tb> <SEP> secoverine <tb> e) Effcct on the synaptosom.ll re-uptake of noradrena line In this test a suspension of rat hypothalamus synaptoso- mes was used. The re-uptake inhibition was expressed in pI50-values, i.e. the negative logarithm of the molar concentration which gives 50% inhibition: EMI5.2 <tb> compound <SEP> pI50 <SEP> <tb> (+)-enantiomer <SEP> of <SEP> 1 <SEP> 4.6 <tb> <SEP> secoverine <tb> racemate <SEP> 5.0 <tb> (-)-enantiomer <SEP> of <SEP> 5.0 <tb> <SEP> secoverine <tb> f) Local anaesthetic activity The anaesthetic activity on the cornea of male mice (18-22 g), 10 animals per dose, was determined according to the method by Weidmann and Petersen, J. Pharmacol. Exp. Ther., 115 (1955), 246. The concentration of the solution of the compounds which gave local anaesthesia in 50% of the animals was determined graphically (EC50 -value): EMI5.3 <tb> compound <SEP> EC50-value <SEP> (% <SEP> w/vol) <tb> (+)-enantiomer <SEP> of <SEP> 0.20 <tb> <SEP> secoverine <tb> racemate <SEP> 0.13 <tb> (-)-enantiomer <SEP> of <SEP> 0.08 <tb> <SEP> secoverine <tb> It appears from test d) that there is no difference between the racemate and the two enantiomers as regards the noradrenaline potentiating activity. It appears from tests e) and f) that the (+ ) -onant iomer of secovcrine has a noradrenaline re-uptake inhibiting and local anaesthetic activity which is substantially weaker than those of the (-)-enantiomer. This means that the much stronger spasmolytic activity of the (+)-enantiomer of secoverine is not related with a proportional increase of undesired side effects. The (+)-enantiomer of secoverine hence is a much more specific spasmolytic than the racemate. The (+)-enantiomer of secoverine can be prepared by methods known per se, by synthesis from optically active intermediates and by resolution of the racemate into its antipodes. A suitable method for example is the reaction of (+)-2-(4-methoxyphenyl)-1-methyldiethylamine with a compound of the formula 3 of the formula sheet, wherein X represents a leaving group, and Y represents a protected keto group. Suitable leaving groups are for example halogen, or the group -OR, wherein R is agtosyl- or tri- flate group. Examples of suitable protecting groups are alkylene ketals, particularly ethylene ketal. The reaction is preferably carried out in an inert solvent such as for example acetonitrile, dimethylformamide, benzene, toluene, acetone and methyl ethyl ketone. The reaction mixture may contain an acid binding agent such as a tertiary amine like triethylamine and pyridine, or an inorganic base such as potassium carbonate. The reaction temperature is between 0 and 200 0C. The protecting group can be removed by means of a hydrolysis with diluted acids such as hydrochloric acid or sulfuric acid, optionally after mixing with ether or acetone, at temperatures between room temperature and the boiling point of the solvent used. Another suitable method for preparing the (+) -enantiomer of secoverine is based on the resolution of the racemate into its optically active antipodes by means of known technjqLEs, for example through fractionated crystallization of diastereomeric salts of the racemic base of the formula 1 with an optically active acid, such as for example (+)-camphorsulfonic acid, (-)-mandelic acid, or or (-)-binaphtylphosphoric acid, and so on. The preparation of the (+)-enantiomer of secoverine will now be described in greater detail with reference to the ensuing specific example. EXAMPLE (+)S-1-cyclohexyl-4-6ethyl(p-methoxy- -methylphenethyl)- -aminog -1-butanone hydrochloride. A solution of 1.4 g (7.2 mmol) of (+)-2-(4-methoxyphenyl)-1-methyl diethylamine (see Rec. trav. chim. 85, (1966), 612) 2.1 g(9.0 mmol) of ethylenecycloacetal of 4-chloro-1-cyclohexyl-1-butanone, 0.7 g (6.9 mmol) of triethylamine and 1.3 g (7.8 mmol) of potassium iodide in 8 ml of dimethyl formamide was heated while stirring at a temperature of 75-800C for 24 hours. After cooling to room temperature, 150 ml of ether were added and the-reaction mixture was washed successively with a 5% soda solution and water. The formed amino-acetal was hydrolyzed by adding 1 to 2 ml of concentrated hydrochloric acid to the wet ether layer until pH 2-3, after which the inhomogeneous mixture was stirred at room temperature for 3 hours. The mixture was then evaporated under reduced pressure and the residue was taken up in 50 ml of water. The resulting solution was washed a few times with 25 ml ether portions, then made basic with crystal soda until pH 9, and then extracted with ether. The resulting crude base of the (+)-enantiomer of secoverine (1.7 g) was purified chromatographically over a silica gel column, in which chloroform and chloroform -methanol (50 : 1) were successively used as an eluent. The collected desired fractions were evaporated under reduced pressure, taken up in 10 ml of absolute ethanol and acidified with 2 N alcoholic hydrochloric acid. After evaporating again, evaporating twice with toluene, and crystallization from an acetone-ether mixture, 1.2 g (3.1. mmol) of the (+)-enantiomer of secoverine having a melting-point of 101-102 C, and > 1 D = + 19.1 (H20) were obtained.

Claims: CLAIMS: 1. A method of preparing pharmaceutical compositions by bringing a spasmolytically active compound of formula 1 of the formula sheet, or a salt thereof, into a form suitable for administration, characterized in that (+)-S-1 -cyclohexyl-4- Sethyl-(p-methoxy- ct-methylphenethyl)amino0- -1-butanone or a salt thereof is used as an active substance. 2. Pharmaceutical compositions obtained according to the method as claimed in Claim 1. 3. A method of preparing a compound of formula 1 of the formula sheet or a salt thereof, characterized in that (+)-S-1-cyclohexyl-4-6ethyltp-methoxy- -methylphen- ethyl)amino3-1-butanone or a salt thereof is prepared by converting (+)-1-(4-methoxyphenyl)-1-methyldiethylamine (of formula 2) with a compound of the formula 3, wherein X represents a leaving group, and Y is a protected keto group. 4. Process according to claim 3, characterized in that the racemate of the formula 1 is resolved by a method known for analogous compounds. 5. (+)-S-1-cyclohexyl-4-6ethyl-(p-methoxy-Ct- -methylphenethyl)amino0-1-butanone and the salts thereof. 6. A method of treating spasms, characterized in that a compound is used as claimed in Claim 5.

Inventors: HARTOG, JAN, VAN WIJNGAARDEN, INEKE, ZWAGEMAKERS, JOHANNES MARIA ANTONIUS
Applicants: DUPHAR INTERNATIONAL RESEARCH B.V
Application year: 1983
Main classification: C07C97
IPC codes: A61K31, C07C213, C07C67, C07C225